Featured Research

from universities, journals, and other organizations

Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both

Date:
November 14, 2013
Source:
Georgetown University Medical Center
Summary:
A molecule that helps cells stick together is significantly over-produced in two very different diseases -- rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial.

A molecule that helps cells stick together is significantly over-produced in two very different diseases -- rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial.

The study, published in Oncotarget, was led by investigators at Georgetown University Medical Center (GUMC), and included collaborators from Harvard and Columbia Universities, Mayo Clinic and Queen's University in Belfast, Northern Ireland.

"Our findings suggest that cadherin-11 is important for cancer progression as well as rheumatoid arthritis -- for reasons we do not fully understand. Nevertheless, we are rapidly translating this discovery for use in the clinic," says the study's senior investigator, Stephen Byers, PhD, a professor and molecular oncologist at Georgetown Lombardi Comprehensive Cancer Center, a part of GUMC.

Byers and his Georgetown colleagues, Shahin Assefnia, DVM, Siva Dakshanamurthy, PhD, and Jaime Guidry Auvil, PhD, have found that cadherin-11 is over-expressed in 15 percent of breast cancers, and in many glioblastomas. He believes the molecule also contributes to pancreatic cancer.

"What most of these cancers all have in common is cadherin-11 and a poor prognosis, with no effective therapies," Byers says. "Cadherin-11 expression is required for tumors to grow. If it is blocked, the cancers in cell line studies and in animals just stop growing -- which is really quite striking."

The Georgetown team has developed a small molecule agent to shut down cadherin-11 in cancer, and, by screening drugs now on the market, found that the well known arthritis drug Celebrex acts in a similar way. While it is unlikely that Celebrex could be used as a single agent against cancer because it would be too toxic at the level needed to impair cadherin-11, a Celebrex-related molecule works the same way, and may potentially be less toxic.

Co-author Michael Brenner, MD, at Harvard University, has designed an antibody that can shut down cadherin-11 in rheumatoid arthritis. The Oncotarget study demonstrated that Brenner's antibody worked in animal models of tumors that made cadherin-11.

It was chance that he and Brenner were working on the same molecule at the same time and came to know of each other's work. Coincidentally, co-author Lawrence Shapiro, PhD, at Columbia, was building a crystal structure of cadherin-11 and is now working with Byers and Brenner to show how the molecule binds to Celebrex and other small molecule drug cadherin-11 inhibitors.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both." ScienceDaily. ScienceDaily, 14 November 2013. <www.sciencedaily.com/releases/2013/11/131114094941.htm>.
Georgetown University Medical Center. (2013, November 14). Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2013/11/131114094941.htm
Georgetown University Medical Center. "Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both." ScienceDaily. www.sciencedaily.com/releases/2013/11/131114094941.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins